Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough
News Jun 09, 2009
Alder Biopharmaceuticals, Inc. has announced the expansion of its collaborative alliance with Schering-Plough Corporation. The collaboration continues to be successful in identifying numerous high quality therapeutic monoclonal antibody lead candidates.
Candidates with potential applications to Central Nervous System (CNS) disorders are being identified through the application of Alder’s high throughput antibody selection (ABS) system and yeast production system (Mab Xpress). These technologies are designed to identify and produce best-in-class antibodies.
Under terms of the agreement, Alder will receive an upfront payment, committed funding for Alder personnel who are engaged in the project and milestone payments associated with the advancement of a therapeutic candidate as well as future product royalties.
“This expanded collaboration further validates the promise and potential of Alder’s leading capabilities to expeditiously identify and manufacture therapeutic monoclonal antibodies,” said Randall Schatzman, Ph.D., Chief Executive Officer of Alder. “We look forward to the continued and expanded partnership with Schering Plough, a leader in therapeutic antibody development and commercialization. More broadly, we are pleased to be positively impacting the way in which companies discover and manufacture biotherapeutics.”
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Vapourtec Collaboration with NPM Drives New Flow TechnologyNews
Flow chemistry engineering specialists Vapourtec (UK) have been engaged in a successful collaboration with New Path Molecular Research Ltd (NPM), focusing on the development of new reactor technology and methods for peptide synthesis.READ MORE